CatalystMarker
← board

ONMDW

distress 8/10 · high distress / dilution risk
$0.04-50%today-62% from 52w high
onemednet.com22 employeesEden Prairie, MN
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+18%

Price & events

-61.7% over 6M
$0.03$0.07$0.10Mar 26May 26Jul 264kdilution: 424B3 offering (2026-07-13)dilution: EFFECT shelf_effective (2026-07-10)dilution: S-1/A shelf_registration (2026-07-08)dilution: S-1 shelf_registration (2026-07-01)dilution: 424B3 offering (2026-05-15)dilution: 424B3 offering (2026-03-31)financing: 8-K material_agreement (2026-07-01)
CatalystRating changeDilutionFinancingdashed = today
-49.6%
1D
+9.7%
1W
-49.6%
1M
-49.6%
3M
—
6M
—
1Y
—
2Y
—
5Y
-61.7%
All

Overview

Market Cap
$2.03M
Enterprise Value
$1.97M
Volume
100
52 Week Range
$0.03 – $0.10
Total Shares
54.43M
Float Shares
15.45M
RVOL
0.57x
Beta
1.14

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 54,433,407 · 6 offerings/1y · 0 PIPEs
  • 2026-07-13424B3offering
  • 2026-07-10EFFECTshelf_effective
  • 2026-07-08S-1/Ashelf_registration
  • 2026-07-018-Kmaterial_agreement
  • 2026-07-01S-1shelf_registration
  • 2026-05-15424B3offering
  • 2026-03-31424B3offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.